These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15474711)

  • 1. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.
    Iskedjian M; Walker JH; De Serres G; Einarson TR
    Paediatr Drugs; 2005; 7(2):123-36. PubMed ID: 15871632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
    Iskedjian M; De Serres G; Einarson TR; Walker JH
    Vaccine; 2010 Jan; 28(3):714-23. PubMed ID: 19895923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.
    Greer AL; Fisman DN
    Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.
    Scuffham PA; McIntyre PB
    Vaccine; 2004 Jul; 22(21-22):2953-64. PubMed ID: 15246632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
    Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
    Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of pertussis vaccination in adults.
    Lee GM; Murphy TV; Lett S; Cortese MM; Kretsinger K; Schauer S; Lieu TA
    Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
    Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
    Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.
    Itatani T; Shimizu S; Iwasa M; Ohkusa Y; Hayakawa K
    Vaccine; 2013 Jun; 31(27):2891-7. PubMed ID: 23570987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.